Catalog No.S2803 Synonyms: TOK-001

For research use only.

Galeterone (TOK-001) is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2.

Galeterone Chemical Structure

CAS No. 851983-85-2

Selleck's Galeterone has been cited by 6 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Other Androgen Receptor Products

Biological Activity

Description Galeterone (TOK-001) is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2.
CYP17 [1]
(Cell-free assay)
Androgen Receptor [1]
300 nM 384 nM
In vitro

Galeterone is effective at preventing binding of [3H]-R1881 to the mutant LNCaP AR (T877A) with IC50 of 845 nM. Galeterone inhibits the DHT-induced proliferation of LNCaP and LAPC4 cells in a dose-dependent manner with IC50 of 6 μM and 3.2 μM, respectively. [1] Galeterone also inhibits the binding of [3H]-R1881 to the T575A mutant AR in PC3 cells with IC50 of 454 nM. Galeterone potently inhibits the proliferation of LNCaP and LAPC4 cells in the absence of DHT stimulation with IC50 of 2.6 μM and 4 μM, respectively. Furthermore, Galeterone treatment increases the degradation rate of the AR in a dose-dependent manner. [2] Galeterone potently inhibits the growth of the androgen-independent cell lines PC-3 and DU-145 in a dose-dependent manner with GI50 of 7.82 μM and 7.55 μM, respectively. Galeterone induces the endoplasmic reticulum stress response resulting in down-regulation of cyclin D1 protein expression and cyclin E2 mRNA. [3] Galeterone effectively inhibits proliferation of HP-LNCaP and C4-2B cell lines with IC50 of 2.9 μM and 9.7 μM, respectively. Galeterone treatment at 1 μM effectively inhibits androgen receptor activation in LNCaP cells (50%) and HP-LNCaP cells (70%). Galeterone decreases activation of the androgen receptor in both LNCaP cells and HP-LNCaP cells with IC50 of 1 μM and 411 nM, respectively, and down-regulates androgen receptor protein expression by 50% after 24 hour of treatment. [4] Galeterone reduces AR protein and mRNA expression, antagonizes AR-dependent promoter activation induced by androgen, and significantly reduces the phospho-4EBP1 levels. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human PC3 cells M3;NU2Z2dmO2aX;uJIF{e2G7 NHrSc|ZFcXOybHHj[Y1mdnRib3[gX|NJZVJzOEixJIZzd21iYX7kdo9o\W5icnXj[ZB1d3JiaX6gbJVu[W5iUFOzJINmdGy|LDDFR|UxRTBwNEC1JO69VQ>? MorDNlU2QTFyNk[=
human LNCaP cells MUPGeY5kfGmxbjDhd5NigQ>? NV6zTW1rOiCq M2n0ZmRqe3CuYXPlcYVvfCCxZjDbN2heWjF6OEGg[pJwdSCDUjDpckBpfW2jbjDMUmNiWCClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKGGwYXz5d4l{NCCHQ{WwQVAvPjdizszN NGHU[WUzOzdzM{W2Oy=>
human CWR22Rv1 cells MmPwSpVv[3Srb36gZZN{[Xl? MWTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEOZUkKyVpYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDQRXJRKGOuZXH2ZYdm NFG1ZoIzOzdzM{W2Oy=>
human LNCAP cells MV3GeY5kfGmxbjDhd5NigQ>? MXi1JO69VQ>? NXzsNFhOPDhiaB?= NEK4OYVFd3ewIILl[5Vt[XSrb36gc4YhSVJicILveIVqdiCneIDy[ZN{cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDVidV2gZYZ1\XJiNEigbJJ{KGK7IFTBVGkhe3SjaX7pcocu[mG|ZXSgbY1ufW6xY4n0c4Np\W2rY3HsJIFv[Wy7c3nz MWKyN|cyOzV4Nx?=
In vivo Administration of Galeterone at 50 mg/kg twice daily is very effective at inhibiting the growth of androgen-dependent LAPC4 human prostate tumor xenograft, with a 93.8% reduction in the mean final tumor volume compared with controls, and it is also significantly more effective than castration. [1] Treatment of Galeterone (0.13 mM/kg twice daily) or Galeterone (0.13 mmol/kg twice daily) plus castration induces regression of LAPC4 tumor xenografts in SCID mice by 26.55% and 60.67%, respectively. Treatments with Galeterone or Galeterone plus castration causes marked reduction in AR protein of 10- and 5-fold, respectively. [2]

Protocol (from reference)

Kinase Assay:


  • In vitro assay of CYP17:

    The in vitro CYP17 inhibitory activity of Galeterone is evaluated using rapid acetic acid releasing assay (AARA), utilizing intact P450c17-expressing E. coli as the enzyme source. It involves the use of [21-3H]-17α-hydroxypregnenolone as the substrate, and CYP17 activity is measured by the amount of tritiated acetic acid formed during the cleavage of the C-21 side chain of the substrate. IC50 value is obtained directly from plots relating percentage inhibition versus inhibitor concentration over appropriate ranges.

Cell Research:


  • Cell lines: LNCaP and LAPC4
  • Concentrations: Dissolved in DMSO, final concentrations ~20 μM
  • Incubation Time: 7 days
  • Method:

    Cells are seeded in 24 well multi-well plates. Cells are treated with the increasing concentration of Galeterone in steroid free medium with or without 1 nM DHT (LNCaP), or 10 nM DHT (LAPC4) and allowed to grow for 7 days. The number of viable cells is compared by MTT assay (LAPC4) or XTT assay (LNCaP) on the 7th day.

Animal Research:


  • Animal Models: Male severe combined immunodeficient (SCID) mice inoculated subcutaneously (s.c.) with LAPC4 cells
  • Dosages: 50 mg/kg
  • Administration: Injection s.c. twice daily

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% hydroxyethyl cellulose
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 388.55


CAS No. 851983-85-2
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02729376 Completed Drug: galeterone Healthy Educational & Scientific LLC March 2016 Phase 1

(data from, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Galeterone | Galeterone supplier | purchase Galeterone | Galeterone cost | Galeterone manufacturer | order Galeterone | Galeterone distributor